Advances In™ Targeted Therapy: New Anticancer Approaches to Treating KRAS-Mutated Solid Tumors

Release Date: May 21, 2021
Expiration Date: May 21, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of patients with KRAS-positive solid tumors, with a forward-looking perspective on how new and novel agents might impact clinical practice. The history of efforts targeting KRAS as a molecular target for treatment, encouraging clinical trial data on KRAS inhibitors, and investigative combination treatment strategies will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.
 

Target Audience

This activity is directed toward oncologists and pathologists involved in the treatment and management of cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

David S. Hong, MD
Professor and Deputy Chair
Department of Investigational Cancer Therapeutics, A Phase I Program
Division of Cancer Medicine
Associate Vice President of Clinical Research
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant: AbbVie, Adaptimmune Therapeutics, Adlai Nortye, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, Erasca, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity Pharmaceuticals, Kite Pharma, Kyowa, Loxo Oncology, MedImmune, Merck, Millennium Pharmaceuticals, Mirati Therapeutics, Mirna Therapeutics, Molecular Templates, Mologen, National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP), Navier, Novartis, Numab, Pfizer, Seagen, Takeda, Turning Point Therapeutics, Verstatem, VM Oncology; Consultant: Adaptimmune, Alpha Insights, Amgen, Aucta Pharmaceuticals, Axiom, Baxter, Bayer, Boxer Capital, COG, Ecor1, Genentech, GLG Pharma, GroupH, Guidepoint Global, HCW Precision, Infinity Pharmaceuticals, Janssen, Medscape, Merrimack Pharmaceuticals, Numab, Pfizer, Prime Oncology, Seagen, STCube, Takeda, Tavistock, Trieza Therapeutics, WebMD; Other: Travel, Accommodations, expenses: AACR, Amgen, ASCO, AstraZeneca, Bayer, Celgene, Eli Lilly, Genentech, Genmab, GlaxoSmithKline, Janssen, Loxo Oncology, Mirna Therapeutics, Pfizer, Philips, SITC, Takeda; Other ownership interest: Molecular Match (Advisor), OncoResponse (Founder), Presagia Inc (Advisor)

Suresh S. Ramalingam, MD, FACP, FASCO
Professor of Hematology and Medical Oncology
Roberto C. Goizueta Distinguished Chair for Cancer Research
Director, Division of Medical Oncology
Deputy Director, Winship Cancer Institute of Emory University School of Medicine
Atlanta, GA

Disclosures: Grant/Research/Support: Advaxis, Amgen, AstraZeneca, Bristol Myers Squibb, Genmab, GlaxoSmithKline, Merck, Takeda, Tesaro; Consultant: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech, GlaxoSmithKline, Lilly, Merck, Roche, Sanofi, Takeda.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.